Skip to main content
OpenTrials
Completed

NCT Number: NCT00235248

Aortic Arch Related Cerebral Hazard Trial (ARCH)

The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology. The objective is to compare the efficacy and tolerance (net benefit) of two antithrombotic strategies in patients with atherothrombosis of the aortic arch and a recent (less than 6 months) cerebral or peripheral embolic event.

Hypothesis:

The association of clopidogrel 75 mg/d plus aspirin 75 mg/d is 25% more effective than an oral anticoagulant (target International Normalized Ratio [INR] 2 to 3) in preventing brain infarction, brain hemorrhage, myocardial infarction, peripheral embolism, and vascular death.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

National Stroke Research Institute-Austin Health, Heidelberg Heights, Australia

Loading trial locations.

About this study

Patients with Transient Ischemic attack or brain infarction of unknown cause (no ipsilateral internal carotid artery origin stenosis greater than 70%, no ipsilateral severe intracranial stenosis of an artery supplying the infarcted area, no definite cardiac source of embolism) in the preceding 6 months and atherosclerotic plaques.

≥ 4 mm in the aortic arch, or patients with a peripheral event (e.g. renal infarct) in the preceding 6 months and plaque ≥ 4 mm in the thoracic aorta above the origin of the embolized artery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria:

  • One of the 3 following ischemic events in the preceding 6 months:
  • Transient ischemic attack (TIA)
  • Non-disabling brain infarcts:
  • Inclusion within 6 months after onset
  • Duration of symptoms and signs greater than 24 hours
  • Neurological signs at the time of randomization with a Rankin Scale grade 3 or less
  • With normal computed tomography (CT) scan or CT scan showing a brain infarct (even hemorrhagic infarct)
  • Peripheral embolism
  • Atherosclerotic plaque in the thoracic aorta is defined as wall thickness ≥ 4 mm where the protruding material is the largest, measured at transesophageal echocardiography with multiplane transducer or a plaque less than 4 mm but with mobile component.
  • Informed consent signed
  • Life expectancy > 3 years

Exclusion criteria

  • Other causes of embolism:
  • Cardiac: endocarditis, atrial fibrillation, intra-cardiac thrombus, valvular prosthesis, rheumatic valvulopathy, left ventricular aneurysm, or ejection fraction less than 25%
  • Atherosclerotic stenosis ipsilateral to the embolic territory: internal carotid artery stenosis greater than 70%, or severe (judgment of the investigator) intracranial stenosis, or scheduled carotid endarterectomy (in that case inclusion is possible 30 days after the procedure)
  • Uncommon causes: dissection, vasculitis, procoagulant state, or sickle cell disease
  • Other exclusion criteria:
  • Intercurrent illness with life expectancy less than 36 months
  • Pregnancy and non-menopausal women
  • Unwillingness to participate
  • Poor medication compliance expected
  • Toxicomania
  • Absolute indication for anticoagulant therapy (e.g. atrial fibrillation, intracardiac thrombus, prosthetic valve)
  • Scheduled for carotid endarterectomy (randomization is possible 30 days after endarterectomy)
  • CT scan with an intracranial lesion other than brain infarction (space occupying mass, intracranial hemorrhage)
  • Transesophageal echocardiography (TEE) with plaque ≥ 4 mm in thickness distal to the supposed embolized artery (judgement of the investigator).
  • Contraindication to clopidogrel, aspirin, and oral anticoagulants

Treatment and study plan

Warfarin

Drug

Warfarin

Clopidogrel-aspirin

Drug

Clopidogrel-aspirin

Primary outcomes

  1. New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death

    Time frame: every 4 months

    New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death

Secondary outcomes

  1. Recurrent brain infarction

    Time frame: during the trial

    Recurrent brain infarction

  2. brain infarction and transient ischemic attack (TIA)

    Time frame: during the studing

    brain infarction and transient ischemic attack (TIA)

  3. new vascular events and revascularization procedure

    Time frame: during the trial

    new vascular events and revascularization procedure

  4. vascular death

    Time frame: during the trial

    vascular death

  5. death from all causes

    Time frame: during the trial

    death from all causes

  6. combination of primary end-point and TIA

    Time frame: during the trial

    combination of primary end-point and TIA

  7. revascularization procedures

    Time frame: during the trial

    revascularization procedures

  8. urgent rehospitalization for ischemic

    Time frame: during the trial

    urgent rehospitalization for ischemic

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Bristol-Myers Squibb
  • National Health and Medical Research Council, Australia
  • Sanofi

Registry information

Official study title

Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery

Acronym: ARCH

Important dates

Study start
2002
Primary completion
2010
Study completion
2012
First posted
Oct 10, 2005
Registry last updated
Jul 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.